Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decrease in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 955,300 shares, a decline of 39.2% from the February 13th total of 1,570,000 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average daily volume of 5,260,000 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Price Performance

VRPX opened at $0.17 on Friday. The company has a 50-day moving average of $0.28 and a 200-day moving average of $0.48. Virpax Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $4.83.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.